Physician profile
Rayen Ayoub Chakra
NPI 1033608765
$3,383.74
in general payments reported to CMS, 2019-2025
19 companies · $2,254 in 2025
The $2,254 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.37 · 2023: $409 · 2024: $695 · 2025: $2,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636 · Travel and Lodging: $654 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,636.05 |
| Travel and Lodging | $654.32 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $1,230.58 | 2024-2025 | Brinsupri, Arikayce |
| Shockwave Medical, INC | $598.86 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Viiv Healthcare Company | $438.02 | 2023-2025 | Dovato, Cabenuva |
| Melinta Therapeutics, LLC | $360.29 | 2023-2025 | Kimyrsa, Rezzayo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.55 | 2025 | Lifevest |
| Theratechnologies INC. | $116.64 | 2022-2025 | Trogarzo, Egrifta |
| Paratek Pharmaceuticals, INC. | $102.93 | 2024-2025 | Nuzyra |
| Gilead Sciences, INC. | $96.01 | 2023-2025 | Veklury |
| Aimmune Therapeutics, INC. | $56.72 | 2024-2025 | Vowst |
| Eisai INC. | $40.87 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.88 | 2024-2025 | Zerbaxa, Delstrigo, Pifeltro |
| Smith+Nephew, INC. | $34.83 | 2024-2025 | Collagenase Santyl |
| Philips North America LLC | $31.35 | 2025 | Vest Therapy Und |
| Alexion Pharmaceuticals, INC. | $27.06 | 2023 | Ultomiris |
| Convatec INC. | $25.98 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.70 | 2023 | Teflaro |
| Lilly USA, LLC | $16.75 | 2025 | Kisunla |
| Averitas Pharma INC. | $15.86 | 2023 | Qutenza |
| Tetraphase Pharmaceuticals, INC. | $13.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rayen Ayoub Chakra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.